A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer

Clinical trial NCT05261269 · COMPLETED

Trial details

NCT number: NCT05261269
Sponsor: Dantari, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-negative Metastatic Breast Cancer

Start date: 2022-02-02
Primary completion: 2023-09-13
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.